NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization192.01 mln
Float92.42 mln
Earnings Date08/11/2026
EPS
0.38
Marginal
P / E
5.29
Undervalued
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-1.5
Manipulation likely
1-Year Forecast
4.60
Transformational upside
Relative Strength
16
/ 100
Significantly lagging
Business Description
Compugen is an Israeli biotech company focused on discovering and developing new cancer treatments, with operations spanning the United States and Europe. Its most advanced programs include several antibody-based therapies being tested in clinical trials, targeting cancer pathways that help tumors evade the immune system. The company works alongside major pharmaceutical partners such as Bristol-Myers Squibb, AstraZeneca, and Gilead Sciences to advance these treatments toward patients. Founded in 1993 and based in Holon, Israel, Compugen also maintains a broader early-stage research pipeline aimed at overcoming various forms of immune resistance in cancer.
